<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03264911</url>
  </required_header>
  <id_info>
    <org_study_id>GASPARD</org_study_id>
    <nct_id>NCT03264911</nct_id>
  </id_info>
  <brief_title>Group A Pharyngitis in Children: The GASPARD Study</brief_title>
  <acronym>GASPARD</acronym>
  <official_title>Group A Streptococcal Pharyngitis: Six Days Amoxicillin, oR Six Days Placebo in Children Between 3 and 15 Years Old:a Randomized, Double Blinded, Multicentred, Non-inferiority Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Klara Posfay-Barbe</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Gertrude Von Meissner Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Recherche et Développement des HUG</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Société académique de Genève</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Geneva</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluate the necessity to treat with antibiotics GAS pharyngitis in children in Switzerland.&#xD;
      The null hypothesis is that antibiotic treatment is not necessary for GAS pharyngitis in this&#xD;
      population.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All children between 3 -15 years old with clinical symptoms suggestive of pharyngitis (Mc&#xD;
      Isaac score ≥3) and a microbiological test (rapid antigen detection) positive for group A&#xD;
      Streptococcus (GAS) will be included in the study. In order to assess the strain of GAS as&#xD;
      well as to identify co-infected children with respiratory virus, a throat culture and a&#xD;
      nasopharyngeal swab will be performed, as well as a standard questionnaire and a standard&#xD;
      physical exam. At this time, children will be randomized to either 6 days of amoxicilline or&#xD;
      6 days of placebo treatment. During the treatment period, the investigators will ask the&#xD;
      parents/legal guardians of the patients to pay close attention to the evolution of the&#xD;
      symptoms (fever, pain, exudates…) as well as the treatment's adverse event, and to report&#xD;
      their presence or absence in a dairy form. At day three after initiation of treatment, a&#xD;
      standardized clinical evaluation will be completed by phone to identify if the patient still&#xD;
      has symptoms of pharyngitis or signs of suppurative complications. One month after the&#xD;
      inclusion in the study, a throat culture, a standardized questionnaire as well as a clinical&#xD;
      evaluation will be performed to identify if the patient has or had signs of non-suppurative&#xD;
      complications and non-resolving infection. Six month and one year after inclusion, a phone&#xD;
      call will evaluate the possible relapses, recurrences and complications of GAS infection with&#xD;
      a standardized questionnaire. GAS strains will be analyzed to identify their unique&#xD;
      fingerprint and viral coinfections will be reported to possibly identify cofactors for&#xD;
      increased complication rates.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">January 27, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2018</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>prospective, randomized, interventional, placebo-controlled, double-blinded, multicentric clinical trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Non inferiority</measure>
    <time_frame>up to 1 month</time_frame>
    <description>Duration of fever and other clinical signs/symptoms in not treated children versus treated</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of consultations for pharyngitis</measure>
    <time_frame>1 year</time_frame>
    <description>To evaluate number of repeated consultations with pediatrician due to non-resolving/recurrent symptoms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>suppurative complications</measure>
    <time_frame>1 year</time_frame>
    <description>to evaluate rates of suppurative complications (acute otitis media-sinusitis-quinsy-cellulitis-impetigo) of GAS infections</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>non-suppurative complications</measure>
    <time_frame>1 year</time_frame>
    <description>to evaluate rates of non-suppurative complications(ARF-glomerulonephritis-scarlet fever) of GAS infections</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>eradication</measure>
    <time_frame>1 month</time_frame>
    <description>to evaluate bacteriological eradication rates of the initial pathogen</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>co-infections</measure>
    <time_frame>at inclusion</time_frame>
    <description>to discover if respiratory viruses are detected as co-infections in children with GAS pharyngitis upon initial presentation and during a recurrent episode</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GAS strains</measure>
    <time_frame>1 month</time_frame>
    <description>to investigate the biology and genetic structure of GAS strains in Switzerland.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">360</enrollment>
  <condition>Group A Streptococcal Pharyngitis</condition>
  <arm_group>
    <arm_group_label>amoxicillin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Children will be randomized to receive, after consent to the study, an antibiotic (amoxicillin approximately 50 mg/kg/day) orally, twice a day for 6 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo arm</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Children will be randomized to receive, after consent to the study, a placebo orally, twice a day for 6 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amoxicillin or Placebo</intervention_name>
    <description>Children will be randomized to either 6 days of amoxicilline or 6 days of placebo treatment</description>
    <arm_group_label>Placebo arm</arm_group_label>
    <arm_group_label>amoxicillin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  3 -15 years old&#xD;
&#xD;
          -  Clinical symptoms suggestive of pharyngitis with MC Isaac score ≥3&#xD;
&#xD;
          -  Rapid-antigen detection test (RADT) positive for GAS-&#xD;
&#xD;
          -  Signed informed parental/patient consent form&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Hypersensitivity to B-lactams&#xD;
&#xD;
          -  concomitant disease which must be treated with antibiotics&#xD;
&#xD;
          -  chronic disease-Immunocompromised&#xD;
&#xD;
          -  Antibiotics within 72 h&#xD;
&#xD;
          -  history of ARF,scarlet fever,impetigo,acute glomerulonephritis&#xD;
&#xD;
          -  Family history of ARF&#xD;
&#xD;
          -  Complicated pharyngitis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>15 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Klara Posfay-Barbe</last_name>
    <role>Principal Investigator</role>
    <affiliation>Coordinator</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Klara Posfay-Barbe</last_name>
    <phone>+4122372 5462</phone>
    <email>klara.posfaybarbe@hcuge.ch</email>
  </overall_contact>
  <location>
    <facility>
      <name>Children's Hospital of Geneva (HUG)</name>
      <address>
        <city>Geneva</city>
        <state>GE</state>
        <zip>1211</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Klara M Posfay-Barbe, MD, MS</last_name>
      <phone>+41 22 372 5462</phone>
      <email>Klara.PosfayBarbe@hcuge.ch</email>
    </contact>
    <investigator>
      <last_name>Klara M Posfay-Barbe, MD, MS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <study_first_submitted>August 15, 2017</study_first_submitted>
  <study_first_submitted_qc>August 28, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 29, 2017</study_first_posted>
  <last_update_submitted>August 28, 2017</last_update_submitted>
  <last_update_submitted_qc>August 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 29, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Geneva</investigator_affiliation>
    <investigator_full_name>Klara Posfay-Barbe</investigator_full_name>
    <investigator_title>Head of Pediatric Infectious Diseases</investigator_title>
  </responsible_party>
  <keyword>pharyngitis</keyword>
  <keyword>amoxicillin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharyngitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amoxicillin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

